文献速递血脂与心血管预防

口服PCSK9抑制剂Enlicitide对比口服非他汀类药物:3期随机临床试验

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-03-30

这项3期随机双盲试验纳入301例他汀治疗成人(LDL-C≥55 mg/dL且有主要ASCVD事件,或LDL-C≥70 mg/dL且中高危),随机接受Enlicitide 20 mg、贝派地酸180 mg、依折麦布10 mg或贝派地酸+依折麦布治疗56天。Enlicitide降低LDL-C 64.6%,优于各对照药,安全性与对照药相似。

要点

  • Enlicitide 20 mg降低LDL-C 64.6%,显著优于贝派地酸、依折麦布及联合治疗。
  • Enlicitide对ApoB和非HDL-C的降低幅度也显著大于各口服非他汀对照药。
  • Enlicitide不良事件和因不良事件停药比例与各对照药相似。

核心结论

  • 在他汀治疗且已有主要ASCVD事件或首次事件风险增高的成人中,Enlicitide降低LDL-C、ApoB和非HDL-C的幅度大于其他口服非他汀类药物。

研究设计与样本

  • 3期随机双盲活性对照试验,301例他汀治疗成人按2:1:1:2随机分配至Enlicitide 20 mg(n=101)、贝派地酸180 mg(n=50)、依折麦布10 mg(n=50)或贝派地酸180 mg+依折麦布10 mg(n=100),每日一次治疗56天。
  • 纳入标准:年龄≥18岁,LDL-C≥55 mg/dL且有主要ASCVD事件,或LDL-C≥70 mg/dL且首次事件中高危。

主要发现

  • 从基线至第56天LDL-C平均百分比变化:Enlicitide -64.6%(95%CI:-68.3%至-60.9%),贝派地酸 -6.3%(95%CI:-13.5%至0.8%),依折麦布 -27.8%(95%CI:-32.3%至-23.4%),贝派地酸+依折麦布 -36.5%(95%CI:-40.8%至-32.2%);Enlicitide优于各对照药(所有P<0.001)。
  • Enlicitide对ApoB和非HDL-C的降低幅度也大于各对照药(所有P<0.001)。

临床怎么用

  • 对于他汀单药治疗未达LDL-C目标的成人,Enlicitide可作为口服非他汀类附加治疗选择。

局限性

  • 原文未报告长期心血管结局、依从性及特定亚组数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many adults fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals on statin monotherapy, requiring additional nonstatin lipid-lowering medication. Enlicitide, an oral proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor, lowered LDL-C by 60% compared with placebo; its efficacy compared with other oral nonstatin therapies has yet to be examined. OBJECTIVES: This study assessed the efficacy of enlicitide, a novel oral PCSK9 inhibitor, vs other oral nonstatin therapies. METHODS: In this phase 3, randomized, double-blind, active-comparator trial, statin-treated adults aged ≥18 years with LDL-C ≥55 mg/dL and a previous major atherosclerotic cardiovascular disease (ASCVD) event, or LDL-C ≥70 mg/dL if at intermediate to high risk for a first event, were randomized in 2:1:1:2 fashion to 20 mg enlicitide (n = 101), 180 mg bempedoic acid (n = 50), 10 mg ezetimibe (n = 50), or 180 mg bempedoic acid plus 10 mg ezetimibe (n = 100) once daily for 56 days. The primary endpoint was mean percentage change in LDL-C from baseline to day 56; secondary endpoints included mean percentage changes in apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (nonHDL-C). Safety endpoints included overall adverse events (AEs) and discontinuations due to AEs. RESULTS: Among 301 randomized participants (mean age 64.4 years, 37% female, 98% receiving moderate- to high-intensity statin), 298 (99.0%) completed the trial. The mean percentage change in LDL-C from baseline to day 56 was -64.6% (95% CI: -68.3% to -60.9%) with enlicitide, -6.3% (95% CI: -13.5% to 0.8%) with bempedoic acid, -27.8% (95% CI: -32.3% to -23.4%) with ezetimibe, and -36.5% (95% CI: -40.8% to -32.2%) with bempedoic acid plus ezetimibe; enlicitide was superior to each comparator (all P < 0.001). Reductions in ApoB and nonHDL-C were also greater with enlicitide (all P < 0.001). Proportions of participants with AEs and discontinuations due to AEs were similar across treatment arms. CONCLUSIONS: In statin-treated adults with a history of a major ASCVD event or at increased risk for a first event, enlicitide achieved greater reductions in LDL-C, ApoB, and nonHDL-C than other oral nonstatin therapies, demonstrating its potential role as an important add-on option when LDL-C goals are not met with the use of statins alone. (A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate [MK-0616, Oral PCSK9 Inhibitor] Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia [MK-0616-018] [CORALreef AddOn; NCT06450366).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Catapano AL, Mikhailova E, Navar AM, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol. 2026. PMID: 42017875. doi:10.1016/j.jacc.2026.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。